Precision medicine, new Gsk-Tempus agreement

GSK has signed a three-year agreement with Tempus, a US company of precision treatments, which gives pharmaceuticals access to the platform with an artificial intelligence system, including the library with anonymous patient data. Thanks to the tools of Artificial Intelligence and Machine Learning (Ia / Ml), as part of the collaboration with Tempus – explains a note released today by the pharmaceutical company – Gsk will be able to improve the design of clinical trials, accelerate the enrollment of participants and identify with precision drug targets. This will contribute to GSK’s greater success rate in research and development and the availability of more personalized treatment to patients in a faster time frame. The new agreement is part of the collaboration started in 2020 on the enrollment in clinical trials of patients with specific types of cancer. Now GSK will be able to expand access to anonymous patient data with greater detail of the pathology. The Tempus dataset draws on the work of more than 40% of American oncologists working in university medical centers and community hospitals. “This collaboration – says Tony Wood, Chief Scientific Officer of GSK – will provide GSK with unique knowledge to discover better treatments and transform drug research. Tempus complements the work that our team is already carrying out by crossing genomics and machine learning, both in basic research and in clinical trials. “Gsk’s investments in human genetics, functional genomics and Ai / Ml – explains the note – have enabled the more than double the number of targets in its initial 2017 portfolio and increase the percentage of those obtained with genetic support by more than 70%. Genetically verified medicines are twice as likely to become registered medicines. As a leader in precision medicine applied to artificial intelligence, Tempus has developed a platform that allows you to quickly test complex biomarker hypotheses. Machine learning is in fact an important component in selecting patients who could benefit from drug candidates in Gsk’s future portfolio. “The data-first approach (data first, Ed) d the GSK in therapeutic research – says Eric Lefkofsky, founder and CEO of Tempus – is in line with ours. We believe Tempus has the resources and capabilities to integrate GSK’s passion for ‘data science’ in a way that others cannot, given the breadth and depth of our platform. We both share a commitment to provide patients with more personalized treatment options to help them live longer, healthier lives. “GSK and Tempus are currently collaborating on an open-label Phase II study, which applies an innovative data-driven approach (data -driven) to speed up and simplify study times. This includes acceleration in protocol development and site selection, with IT support, in less than 60 days with initial patient enrollment within three months of study launch The expansion of the collaboration provides for a minimum financial commitment over three years, for which GSK has made an initial payment of $ 70 million, and GSK also has an option to extend it for another two years.